FibroGen Inc - ESG Rating & Company Profile powered by AI
The Disclosure rating includes seventeen United Nations SDGs including: 'No Poverty', 'Industry, Innovation & Infrastructure' and 'Life on Land'. The analysis of FibroGen Inc employs data from across the internet and also from available documents by FibroGen Inc. Browse to the end of this page for potential risks for FibroGen Inc based on industry, location and size.
FibroGen Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.1; made up of an environmental score of 0.0, social score of 1.6 and governance score of 1.6.
1.1
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1779 | Taisho Pharmaceutical Holdings Co Ltd | 1.2 | Low |
| 1779 | VBI Vaccines Inc | 1.2 | Low |
| 1810 | FibroGen Inc | 1.1 | Low |
| 1810 | Captor Capital Corp | 1.1 | Low |
| 1810 | Century Therapeutics Inc | 1.1 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does FibroGen Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes FibroGen Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes FibroGen Inc report the average age of the workforce?
Sign up for free to unlockDoes FibroGen Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes FibroGen Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes FibroGen Inc disclose cybersecurity risks?
Sign up for free to unlockDoes FibroGen Inc offer flexible work?
Sign up for free to unlockDoes FibroGen Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes FibroGen Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes FibroGen Inc conduct supply chain audits?
Sign up for free to unlockDoes FibroGen Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes FibroGen Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes FibroGen Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes FibroGen Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes FibroGen Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes FibroGen Inc disclose water use targets?
Sign up for free to unlockDoes FibroGen Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid FibroGen Inc have a product recall in the last two years?
Sign up for free to unlockDoes FibroGen Inc disclose incidents of discrimination?
Sign up for free to unlockDoes FibroGen Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas FibroGen Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes FibroGen Inc disclose parental leave metrics?
Sign up for free to unlockDoes FibroGen Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes FibroGen Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes FibroGen Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes FibroGen Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes FibroGen Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes FibroGen Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs FibroGen Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes FibroGen Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes FibroGen Inc disclose its waste policy?
Sign up for free to unlockDoes FibroGen Inc report according to TCFD requirements?
Sign up for free to unlockDoes FibroGen Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes FibroGen Inc disclose energy use targets?
Sign up for free to unlockDoes FibroGen Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes FibroGen Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for FibroGen Inc
These potential risks are based on the size, segment and geographies of the company.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.